Abstracts tagged "remission"

Abstract Number: 2851 • 2019 ACR/ARP Annual Meeting
Limiting Factors of Reaching ACR/EULAR Boolean Remission in Early RA Patients Treated According to Current Recommendations
Nina Sundlisater¹, Anna-Birgitte Aga ², Ulf Sundin ³, Hilde Hammer ¹, Till Uhlig ⁴, Tore Kvien ⁴, Espen Haavardsholm ⁴ and Siri Lillegraven ⁵, ¹Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, ²Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Oslo, Norway, ³Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway. University of Oslo, Oslo, Norway, Oslo, Oslo, Norway, ⁴Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁵Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway
Background/Purpose: Abrogation of inflammation is important to prevent irreversible joint damage and maximize health-related quality of life in early RA patients. The ACR/EULAR Boolean remission…
Abstract Number: 2908 • 2019 ACR/ARP Annual Meeting
Remission in Patients with Rheumatoid Arthritis Receiving Triple Therapy Compared to Biological Therapy – A Swedish Nationwide Register Study
Hanna Källmark¹, Jon Einarsson ², Jan-Åke Nilsson ³ and Meliha Kapetanovic ², ¹Lund University, Lund, Sweden, ²Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Section of Rheumatology, Lund and Malmö, Sweden, Lund, Sweden, ³Skane University Hospital, Lund and Malmö, Sweden, Lund, Sweden
Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend a treat-to-target approach with early treatment initiation of disease-modifying antirheumatic drugs (DMARDs), most commonly methotrexate (MTX),…
Abstract Number: 837 • 2019 ACR/ARP Annual Meeting
Does Discordance Between Baseline Patient’s and Evaluator’s Global Assessment of Disease Activity Impact Retention and Remission Rates of a First TNF Inhibitor in Patients with Axial Spondyloarthritis? Data from the EuroSpA Research Collaboration Network
Brigitte Michelsen¹, Lykke Midtbøll Ørnbjerg ², Anne Gitte Loft ³, Tore Kvien ⁴, Adrian Ciurea ⁵, Herman Mann ⁶, Kari K. Eklund ⁷, Ayten Yazici ⁸, Maria José Santos ⁹, Johan Askling ¹⁰, Ziga Rotar ¹¹, Bjorn Gudbjornsson ¹², Manuel Pombo-Suarez ¹³, Catalin Codreanu ¹⁴, Irene van der Horst-Bruinsma ¹⁵, Eirik Kristianslund ¹⁶, Michael J. Nissen ¹⁷, Karel Pavelka ⁶, Nina Trokovic ¹⁸, Nevsun Inanc ¹⁹, Elsa Vieira-Sousa ²⁰, Daniela DiGuiseppe ²¹, Matija Tomsic ²², Arni Jon Geirsson ²³, Ruxandra IONESCU ²⁴, Marleen van de Sande ²⁵, Florenzo Iannone ²⁶, Carlos Sánchez-Piedra ²⁷, Gareth Jones ²⁸, Lise Hyldstrup ², Merete Lund Hetland ²⁹ and Mikkel Østergaard ³⁰, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ⁴Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁵University Hospital Zürich, Zürich, Switzerland, ⁶Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁷ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, ⁸Kocaeli University, Faculty of Medicine, Division of Rheumatology, Kocaeli, Kocaeli, Turkey, ⁹Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹⁰Karolinska Institutet, Stockholm, Sweden, ¹¹UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ¹²Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹³Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ¹⁴Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹⁵Amsterdam University Medical Center, Amsterdam, Netherlands, ¹⁶Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ¹⁷University Hospital Geneva, Geneva, Switzerland, ¹⁸Helsinki University Central Hospital, Helsinki, Finland, ¹⁹Marmara University, Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ISTANBUL, Turkey, ²⁰Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, ²¹Clinical Epidemiology Division, Dept of Medicine Solna, Karolinska Institutet,, Stockholm, Sweden, ²²Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ²³Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, ²⁴SPITALUL CLINIC SFANTA MARIA, Bucharest, ²⁵Amsterdam UMC, Amsterdam, Netherlands, ²⁶Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ²⁷Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²⁸University of Aberdeen, Aberdeen, United Kingdom, ²⁹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ³⁰Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Discordance between baseline patient’s and evaluator’s global assessment of disease activity is common.1 However, the impact of such discordance on retention and remission rates…
Abstract Number: 1172 • 2019 ACR/ARP Annual Meeting
The Relationship Between Subclinical Inflammation and Bone Damage in Patients with Rheumatoid Arthritis Using Multimodality Imaging
Scott Brunet ¹, Peter Salat ², Glen Hazlewood ³, Klaus Engelke ⁴, Cheryl Barnabe ³ and Sarah Manske³, ¹University of Calgary, Calgary, Canada, ²University of Calgary, Calary, Canada, ³University of Calgary, Calgary, AB, Canada, ⁴Erlangen University Hospital, Department of Medicine, Erlangen, Germany
Background/Purpose: Many RA patients in clinical remission have evidence of bone marrow edema (BME) on magnetic resonance imaging (MRI), with radiographic bone damage progression appearing…
Abstract Number: 1242 • 2019 ACR/ARP Annual Meeting
Impact of Smoking Status on Remission in Hidradenitis Suppurativa
Amil Agarwal ¹, Marissa Mangini ¹, Derek Jones ¹, Catherine Hood ¹, Richard Amdur ¹ and Victoria Shanmugam², ¹The George Washington University School of Medicine and Health Sciences, Washington, DC, ²George Washington University, Georgetown, DC
Background/Purpose: Hidradenitis Suppurativa (HS) is an inflammatory disease of the apocrine sweat glands characterized by recurrent abscessing inflammation. The molecular drivers of HS are poorly…
Abstract Number: 1282 • 2019 ACR/ARP Annual Meeting
Female Sex Is a Risk Factor for Failure to Achieve Remission in Polymyositis
Prasanth Lingamaneni¹, Carrie Richardson ², Soumyasri Kambhatla ³ and Augustine Manadan ², ¹John H. Stroger Hospital of Cook County, Chicago, IL, ²Rush University Medical Center, Chicago, IL, ³John H. Stroger Hospital of Cook County, Chicago
Background/Purpose: Adults with polymyositis demonstrate wide variability in responses to treatment, and the risk factors for failure to achieve remission in polymyositis are largely unknown. …
Abstract Number: 1340 • 2019 ACR/ARP Annual Meeting
Patterns of Sustained Remission and Subsequent DMARD Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort
Maria Powell¹, Vivian Bykerk ², Orit Schieir ³, Marie-France Valois ⁴, Susan J. Bartlett ⁵, Louis Bessette ⁶, Gilles Boire ⁷, Carol Hitchon ⁸, Edward Keystone ⁹, Janet Pope ¹⁰, Carter Thorne ¹¹, Diane Tin ¹² and Glen Hazlewood ¹, ¹University of Calgary, Calgary, AB, Canada, ²Hospital for Special Surgery, New York City, NY, ³University of Toronto Dalla Lana School of Public Health, Toronto, ON, Canada, ⁴McGill University, Montreal, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Laval University, Quebec City, QC, Canada, ⁷Sherbrooke University, Sherbrooke, QC, Canada, ⁸University of Manitoba, Winnipeg, Canada, ⁹Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹⁰Western University, London, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Southlake Regional Health Centre, Newmarket, Canada
Background/Purpose: Rheumatoid arthritis (RA) treatment emphasizes aggressive titration of disease-modifying antirheumatic drugs (DMARDs) with the goal of achieving disease remission. This often includes the use…
Abstract Number: 611 • 2018 ACR/ARHP Annual Meeting
Influence of Dose Titration of Concomitant Steroid and Methotrexate during Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice Based on the IORRA Cohort
Yoko Shimizu¹, Eiichi Tanaka¹, Eisuke Inoue^1,2, Kumiko Saka¹, Eri Sugano¹, Naohiro Sugitani^1,3, Moeko Ochiai¹, Rei Yamaguchi¹, Naoki Sugimoto¹, Ayako Nakajima^1,3, Katsunori Ikari¹, Atsuo Taniguchi¹ and Hisashi Yamanaka⁴, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, ³Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, ⁴Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: After the introduction of Biological Disease-Modifying Anti-Rheumatic-Drugs (bDMARDs) for the treatment of patients with active rheumatoid arthritis (RA), clinical remission has become an achievable…
Abstract Number: 1199 • 2018 ACR/ARHP Annual Meeting
The Use of Musculoskeletal Ultrasound to Assess Remission in Patients with Rheumatoid Arthritis
Myriam Allen¹, Maggie Larche² and Karen A. Beattie², ¹Rheumatology, McMaster University, Hamilton, ON, Canada, ²Medicine, McMaster University, Hamilton, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) should achieve remission rapidly to avoid irreversible joint sequela. Studies have shown that patients with apparent clinical remission have…
Abstract Number: 1282 • 2018 ACR/ARHP Annual Meeting
Influence of Renal Function on the Velocity of Tophus Resolution and Achievement of Disease Remission in Patients with Chronic Refractory Gout Treated with Pegloticase
Brian F. Mandell¹, Naomi Schlesinger², N. Lawrence Edwards³, Anthony Yeo⁴ and Peter E. Lipsky⁵, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ³Rheumatology, University of Florida Health Science Center, Gainesville, FL, ⁴Horizon Pharma, Lake Forest, IL, ⁵AMPEL BioSolutions, Charlottesville, VA
INFLUENCE OF RENAL FUNCTION ON THE VELOCITY OF TOPHUS RESOLUTION AND ACHEIVEMENT OF DISEASE REMISSION IN PATIENTS WITH CHRONIC REFRACTORY GOUT TREATED WITH PEGLOTICASEBackground/Purpose: Impaired…
Abstract Number: 1453 • 2018 ACR/ARHP Annual Meeting
Correlation between Clinical and Ultrasonographic Remission? the Effect of Non-Inflammatory Patient-Based Factors on Different Remission Definitions
Ummugulsum Gazel¹, Sibel Yilmaz Oner², Gulsen Ozen³, Yasemin Yalçınkaya³, Pamir Atagunduz³, Haner Direskeneli³ and Nevsun Inanc³, ¹Rheumatology, Marmara University faculty of Medicine, Istanbul, Turkey, ²Rheumatology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ³Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: In this study, we aimed to investigate the concordance of ultrasonographic remission with other remission criteria and to show the influence of non-inflammatory patient-induced…
Abstract Number: 1496 • 2018 ACR/ARHP Annual Meeting
Sex Differences in the Achievement of Clinical Remission and Low MRI Synovitis Scores in Rheumatoid Arthritis
Joshua Baker¹, Mikkel Østergaard², Carson Maynard³, Michael D. George⁴, Daniel Baker⁵ and Philip G. Conaghan⁶, ¹Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ³Rheumatology, University of Pennsylvania, Philadlphia, PA, ⁴Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵Johnson & Johnson, Spring House, PA, ⁶University of Leeds, Leeds, UK, Leeds, United Kingdom
Background/Purpose: Several prior studies have demonstrated poor clinical responses and reduced likelihood of achievement of remission among women with rheumatoid arthritis (RA). We aimed to…
Abstract Number: 1930 • 2018 ACR/ARHP Annual Meeting
Histologic and Transcriptional Evidence of Subclinical Synovial Inflammation in Rheumatoid Arthritis Patients in Clinical Remission
Dana Orange¹, Phaedra Agius², Edward F. DiCarlo³, Serene Z. Mirza⁴, Cristina Rozo⁵, Tania Pannellini⁵, Mark P. Figgie⁶, William H. Robinson⁷, Jackie Szymonifka⁵, Vivian P. Bykerk⁵, Laura T. Donlin⁸ and Susan M. Goodman⁵, ¹Rockefeller University, New York, NY, ²New York Genome Center, New York, NY, ³Laboratory Medicine, Hospital for Special Surgery, New York, NY, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Hospital for Special Surgery, New York, NY, ⁶Surgery, Hospital for Special Surgery, New York, NY, ⁷Stanford University, Palo Alto, CA, ⁸Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: Rheumatoid Arthritis (RA) patients in clinical remission may still develop structural damage that has been attributed to ongoing synovial inflammation, sometimes only detectable…
Abstract Number: 2820 • 2018 ACR/ARHP Annual Meeting
Sustained Clinical Remission after Discontinuation of Infliximab with a Raising Dose Strategy in Patients with Rheumatoid Arthritis (RRRR study): A Randomized Controlled Trial
Yoshiya Tanaka¹, Koji Oba^2,3, Takao Koike^4,5, Nobuyuki Miyasaka⁶, Tsuneyo Mimori⁷, Tsutomu Takeuchi⁸, Shintaro Hirata⁹, Eiichi Tanaka¹⁰, Hidekata Yasuoka¹¹, Yuko Kaneko⁸, Kosaku Murakami⁷, Tomohiro Koga¹², Kazuhisa Nakano¹³, Koichi Amano¹⁴, Kazuyasu Ushio¹⁵, Tatsuya Atsumi¹⁶, Masayuki Inoo¹⁷, Kazuhiro Hatta¹⁸, Shinichi Mizuki¹⁹, Shohei Nagaoka²⁰, Shinichiro Tsunoda²¹, Hiroaki Dobashi²², Nao Horie³ and Norihiro Sato³, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Interfaculty Initiative in Information Studies, The University of Tokyo, Tokyo, Japan, ³Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan, ⁴Hokkaido Medical Center for Rheumatic Diseases, Sapporo, Japan, ⁵NTT Sapporo Medical Center, Sapporo, Japan, ⁶Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ⁷Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁸Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁹Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ¹⁰Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, tokyo, Japan, ¹²Center for Bioinformatics and Molecular Medicine, Nagasaki University, Graduate School of Biomedical Sciences, Nagasaki, Japan, ¹³The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁴Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ¹⁵Ushio Clinic, Osaka, Japan, ¹⁶Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ¹⁷Utazu hospital, Utatsu-cho, Japan, ¹⁸Department of General Medicine, Tenri Hospital, Tenri, Japan, ¹⁹Center for Rheumatic Diseases, Matsuyama Red Cross Hospital, Matsuyama, Japan, ²⁰Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, ²¹Division of Rheumatology Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ²²Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Kagawa University, Miki-cho, Japan
Background/Purpose: Infliximab (IFX), a TNF inhibitor, is one of the most widely used biological disease-modifying antirheumatic drugs. Recent studies indicated that baseline levels of serum…
Abstract Number: 2821 • 2018 ACR/ARHP Annual Meeting
Dose Tapering and Discontinuation of Biological Therapy in Rheumatoid Arthritis Patients in Routine Care – 2-Year Outcomes and Predictors
Cecilie Heegaard Brahe¹, Simon Krabbe¹, Mikkel Østergaard¹, Lykke Midtbøll Ørnbjerg¹, Daniel Glinatsi¹, Henrik Rogind¹, Hanne Slott Jensen², Annette Hansen³, Jesper Nørregaard⁴, Søren Jacobsen⁵, Lene Terslev¹, Tuan Khai Huynh⁴, Dorte Vendelbo Jensen⁶, Natalia Manilo², Karsten Asmussen², Per Brown-Frandsen⁵, Mikael Boesen⁷, Zoreh Rastiemadabadi⁷, Lone Morsel-Carlsen⁷, Jakob M. Møller⁸, Niels Steen Krogh⁹ and Merete Lund Hetland¹⁰, ¹Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark, ²Center for Rheumatology and Spine Diseases, Bispebjerg-Frederiksberg Hospital, Copenhagen, Copenhagen, Denmark, ³Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte, Gentofte, Denmark, Copenhagen, Denmark, ⁴Center for Rheumatology and Spine Diseases, Nordsjællands Hospital, Hillerød, Denmark, Hillerød, Denmark, ⁵Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ⁶Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte, Gentofte, Copenhagen, Denmark, ⁷Department of Radiology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Copenhagen, Denmark, ⁸Department of Radiology, Copenhagen University Hospital Herlev, Copenhagen, Denmark, ⁹ZiteLab ApS, Copenhagen, Denmark, ¹⁰DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark
Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care – 2-year outcomes and predictors Background/Purpose: A cohort of routine care…